<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02447653</url>
  </required_header>
  <id_info>
    <org_study_id>BMETAU09</org_study_id>
    <nct_id>NCT02447653</nct_id>
  </id_info>
  <brief_title>Hydroxyapatite (HA) Coating Versus Plasma Porous Spray (PPS) in Press-fit Acetabular Components Early Outcomes With DEXA</brief_title>
  <official_title>A Randomised Controlled Study Comparing Hydroxyapatite (HA) Coating Versus Plasma Porous Spray in Press-fit Acetabular Components Early Outcomes With Dual Energy X-ray Absorptiometry (DEXA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study design comprises a randomized trial of patients undergoing primary total hip&#xD;
      arthroplasty using the G7 acetabular system and Taperloc Complete stem comparing regular&#xD;
      plasma porous spray with HA coating using Bonemaster (BM) in an uncemented cup. DEXA scanning&#xD;
      will be used to measure periprosthetic bone mineral density. Clinical evaluations will be&#xD;
      conducted .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design comprises a randomized trial of patients undergoing primary total hip&#xD;
      arthroplasty using the G7 acetabular system and Taperloc Complete stem comparing regular&#xD;
      plasma porous spray with HA coating using Bonemaster (BM) in an uncemented cup. DEXA scanning&#xD;
      will be used to measure periprosthetic bone mineral density preoperatively and&#xD;
      post-operatively at 6 weeks, 12 weeks, 26 weeks, and 12 months for both the treated and&#xD;
      contralateral hip joint. Clinical evaluations will be conducted preoperatively, and&#xD;
      postoperatively at 6, 12, 26 weeks, 12 months and 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 15, 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Remodelling (DEXA analysis)</measure>
    <time_frame>12 months</time_frame>
    <description>DEXA analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical (Harris Hip Score)</measure>
    <time_frame>24 months</time_frame>
    <description>Harris Hip Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical (Oxford Hip Score)</measure>
    <time_frame>24 months</time_frame>
    <description>Oxford Hip Score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Hydroxyapatite Coating</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G7 HA Acetabular component will be implanted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasma Porous Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>G7 PPS Acetabular component will be implanted</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>G7 HA Acetabular Component</intervention_name>
    <description>G7 HA Acetabular Component</description>
    <arm_group_label>Hydroxyapatite Coating</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>G7 PPS Acetabular Component</intervention_name>
    <description>G7 PPS Acetabular Component</description>
    <arm_group_label>Plasma Porous Spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with osteoarthritis who are candidates for a primary total hip replacement&#xD;
             with uncemented acetabular and femoral components as determined by the surgeon.&#xD;
&#xD;
          2. Male and non-pregnant female patient aged 18 to 70.&#xD;
&#xD;
          3. Patients who understand the conditions of the study and are willing to participate for&#xD;
             the length of the prescribed follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients requiring total hip replacement surgery for a fresh hip fracture.&#xD;
&#xD;
          2. Patients with inflammatory arthritis&#xD;
&#xD;
          3. Patients with metabolic bone disease or taking drugs that affect bone turnover. 4&#xD;
             .Patients requiring revision surgery of a previously implanted total hip replacement&#xD;
             system or patients requiring a conversion surgery from a previous fracture fixation or&#xD;
             hip fusion.&#xD;
&#xD;
        5. Patients with presence of malignancy in the area of the involved hip joint. 6. Patients&#xD;
        who, as judged by the surgeon, are mentally incompetent or are reasonably unlikely to be&#xD;
        compliant with the prescribed postoperative routine and the follow-up evaluation schedule.&#xD;
&#xD;
        7. Patients with other concurrent illnesses that are likely to affect their outcome such as&#xD;
        sickle cell anaemia, systemic lupus erythematosus or renal disease requiring dialysis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gold Coast Centre for Bone and Joint Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Greenslopes Private Hospital</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 8, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

